Hennion & Walsh Asset Management’s Pliant Therapeutics PLRX Stock Holding History

Hennion & Walsh Asset Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-106,705	Closed	-$134K	–	997
2026 Q1	$134K	Sell	106,705 -6,678	-6%	-$8.43K	﹤0.01%	914
2025 Q4	$138K	Buy	113,383 +15,349	+16%	+$23.1K	﹤0.01%	917
2025 Q3	$145K	Sell	98,034 -1,785	-2%	-$2.72K	0.01%	930
2025 Q2	$116K	Sell	99,819 -4,611	-4%	-$6.51K	﹤0.01%	907
2025 Q1	$141K	Sell	104,430 -4,178	-4%	-$25.4K	0.01%	849
2024 Q4	$1.43M	Buy	108,608 +16,634	+18%	+$227K	0.06%	376
2024 Q3	$1.03M	Buy	91,974 +23,685	+35%	+$296K	0.05%	445
2024 Q2	$734K	Buy	+68,289	New	+$880K	0.04%	492

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Hennion & Walsh Asset Management's PLRX Position: Q2 2026 in Review

Hennion & Walsh Asset Management sold out of Pliant Therapeutics (PLRX) in Q2 2026, closing a stake of 106,705 shares — an estimated $134K sold.

Hennion & Walsh Asset Management first reported a position in PLRX in Q2 2024 and held it in 8 quarters. The position peaked at $1.43M in Q4 2024. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

Hennion & Walsh Asset Management reported no remaining Pliant Therapeutics position as of Q2 2026 after selling out during the quarter.
Hennion & Walsh Asset Management sold 106,705 Pliant Therapeutics shares in Q2 2026, an estimated $134K.
Hennion & Walsh Asset Management first reported a position in Pliant Therapeutics in Q2 2024 and held it in 8 quarters.
Hennion & Walsh Asset Management's Pliant Therapeutics position peaked at $1.43M in Q4 2024.
86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.